All News

We are delighted to announce that Mark Chadwick, CEO at Physiomics Plc has been accepted to present at this year’s biopartnering and investment conference. Read more about the conference. ...

Read More

Physiomics is an Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our models are based on sets of mathematical equations that simulate key biological processes, and are used by pharmaceutical companies to accelerate their internal drug discovery and development programs. We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development....

Read More

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics”, taking place at the Moscone Center West, San Francisco, California on 12-16 November 2011. Dr Eric Fernandez, Project Leader at Physiomics, will present on a prototype version of an anti-cancer drug combination and regimen database. Dr...

Read More

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly'), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology.  The projects involve predicting the outcomes of proposed regimens for two Lilly candidate compounds in combination with other drugs. Read...

Read More

Physiomics Plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a collaborative agreement (“Agreement”) with a wholly owned subsidiary of ValiRx plc (AIM: VAL), ValiPharma Limited, a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, relating to the further development and accelerated progress of VAL201, ValiPharma’s anti-cancer compound. Read more...

Read More

Physiomics is delighted to announce the publication by Springer of the book ‘Cancer Systems Biology, Bioinformatics and Medicine’ in the Research and Clinical Applications series. Physiomics’ scientists have written the chapter 14 entitled “Systems biology approaches to cancer drug development.” “This teaching monograph on systems approaches to cancer research and clinical applications provides a unique synthesis, by world-class scientists and doctors, of laboratory, computational, and clinical...

Read More
})(jQuery)